Trial · NCT01907269
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
NCT01907269, Not applicable, Completed, University of Alabama at Birmingham; results first posted 2018-06-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care. Trials, record NCT01907269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01907269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
- NCT number
- NCT01907269
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,684 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Osteoporosis
- Interventions
- Video-based Intervention
- First posted
- 2013-07-24
- Last updated
- 2018-06-26
- Results first posted
- 2018-06-26
- Limitations and caveats
Low rates of osteoporosis treatment initiation; Self-reported fracture history subject to recall bias; Low % of participants reported fracture in 12-months prior to intervention; Low % of participants who interacted with intervention appreciably
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Initiate an Osteoporosis Prescription Medication | 6 months post-intervention | We will assess the number of participants that self-report the initiation of an osteoporosis prescription medication. It will be assessed using a self-completed survey. Osteoporosis prescription medications that will be assessed include: alendronate, calcitonin, denosumab ibandronate, raloxifene, risedronate, teriparatide, and zoledronic acid. We will not include initiation of estrogen hormone therapies as part of the primary outcome. |
| Secondary | Number of Participants Who Reported Use of Calcium and Vitamin D | 6 and 18 months post-intervention | We will assess the use of calcium and vitamin D by participant. This will be assessed on a self-completed survey. Participants will be asked if they are currently taking a calcium supplement and/or vitamin D supplement. |
| Secondary | Number of Participants Who Reported Receipt of Bone Mineral Density (BMD) Testing | 6 and 18 months post-intervention | Self-report of a receipt of a DXA scan (Bone Mineral Density test). |
| Secondary | Number of Participants That Initiate an Osteoporosis Prescription Medication | 18 months | We will assess the number of participants that self-report the initiation of an osteoporosis prescription medication. It will be assessed using a self-completed survey. Osteoporosis prescription medications that will be assessed include: alendronate, calcitonin, denosumab ibandronate, raloxifene, risedronate, teriparatide, and zoledronic acid. We will not include initiation of estrogen hormone therapies as part of the outcome. |
| Other | Number of Participants Who Reported Communicating With a Health Care Provider About Osteoporosis Care | 6 and 18 months post-intervention |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants That Initiate an Osteoporosis Prescription Medication | 6 months post-intervention | For the Intent-to-Treat Analysis the data was imputed for non-responders. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Reported Use of Calcium and Vitamin D | 6 and 18 months post-intervention | For the Intent-to-Treat Analysis the data was imputed for non-responders. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Reported Receipt of Bone Mineral Density (BMD) Testing | 6 and 18 months post-intervention | For the Intent-to-Treat Analysis the data was imputed for non-responders. Surveys for BMD (18 months) included 3 responses. If participants marked option (2) that they had received a BMD, but \> 12 months ago they were excluded from analyses. Thus our overall population analyzed (those marking response 1 or 3) is different than our participant flow. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants That Initiate an Osteoporosis Prescription Medication | 18 months | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Number of Participants Who Reported Communicating With a Health Care Provider About Osteoporosis Care | 6 and 18 months post-intervention | For the Intent-to-Treat Analysis the data was imputed for non-responders. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Initiate an Osteoporosis Prescription Medication | Video-based Intervention | 157 | Participants | ||
| Number of Participants That Initiate an Osteoporosis Prescription Medication | Usual Care | 153 | Participants | ||
| Number of Participants Who Reported Use of Calcium and Vitamin D | Video-based Intervention | Vitamin D (6 months) | 554 | Participants | |
| Number of Participants Who Reported Use of Calcium and Vitamin D | Usual Care | Vitamin D (6 months) | 562 | Participants | |
| Number of Participants Who Reported Use of Calcium and Vitamin D | Video-based Intervention | Calcium (6 months) | 427 | Participants | |
| Number of Participants Who Reported Use of Calcium and Vitamin D | Usual Care | Calcium (6 months) | 437 | Participants | |
| Number of Participants Who Reported Use of Calcium and Vitamin D | Video-based Intervention | Vitamin D (18 months) | 475 | Participants | |
| Number of Participants Who Reported Use of Calcium and Vitamin D | Usual Care | Vitamin D (18 months) | 572 | Participants | |
| Number of Participants Who Reported Use of Calcium and Vitamin D | Video-based Intervention | Calcium (18 months) | 249 | Participants | |
| Number of Participants Who Reported Use of Calcium and Vitamin D | Usual Care | Calcium (18 months) | 310 | Participants |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| 6 Month Outcome Measures Post-interventi | STARTED | Video-based Intervention | 1,342 | |
| 6 Month Outcome Measures Post-interventi | STARTED | Usual Care | 1,342 | |
| 6 Month Outcome Measures Post-interventi | COMPLETED | Video-based Intervention | 953 | |
| 6 Month Outcome Measures Post-interventi | COMPLETED | Usual Care | 1,053 | |
| 6 Month Outcome Measures Post-interventi | NOT COMPLETED | Video-based Intervention | 389 | |
| 6 Month Outcome Measures Post-interventi | NOT COMPLETED | Usual Care | 289 | |
| 18 Month Outcome Measures Post-intervent | STARTED | Video-based Intervention | 1,178 | |
| 18 Month Outcome Measures Post-intervent | STARTED | Usual Care | 1,250 | |
| 18 Month Outcome Measures Post-intervent | COMPLETED | Video-based Intervention | 859 | |
| 18 Month Outcome Measures Post-intervent | COMPLETED | Usual Care | 970 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Video-based Intervention | 0 | 0 |
| Total, all-cause mortality | Usual Care | 0 | 0 |
| Total, other adverse events | Video-based Intervention | 0 | 0 |
| Total, other adverse events | Usual Care | 0 | 0 |
| Total, serious adverse events | Video-based Intervention | 0 | 0 |
| Total, serious adverse events | Usual Care | 0 | 0 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AR060240 | Activating Patients to Reduce Osteoporosis (APROPOS) | SAAG, KENNETH G | UNIVERSITY OF ALABAMA AT BIRMINGHAM | NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES | 2011 to 2015 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Video-based Intervention vs Usual Care: Number of Participants That Initiate an Osteoporosis Prescription Medication | Trial comparisons |
| Video-based Intervention vs Usual Care: Number of Participants That Initiate an Osteoporosis Prescription Medication | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01907269
GET https://conductscience.org/api/trials/v1/NCT01907269/registered